A detailed history of Fmr LLC transactions in Annexon, Inc. stock. As of the latest transaction made, Fmr LLC holds 8,299,720 shares of ANNX stock, worth $60.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,299,720
Previous 9,372,822 11.45%
Holding current value
$60.4 Million
Previous $67.2 Million 39.48%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$4.33 - $6.79 $4.65 Million - $7.29 Million
-1,073,102 Reduced 11.45%
8,299,720 $40.7 Million
Q1 2024

May 13, 2024

SELL
$4.03 - $7.81 $1.26 Million - $2.44 Million
-312,579 Reduced 3.23%
9,372,822 $67.2 Million
Q4 2023

Feb 13, 2024

BUY
$1.63 - $4.63 $15.6 Million - $44.4 Million
9,593,619 Added 10452.61%
9,685,401 $44 Million
Q3 2023

Nov 13, 2023

SELL
$2.13 - $3.84 $2.8 Million - $5.04 Million
-1,313,496 Reduced 93.47%
91,782 $216,000
Q2 2023

Aug 11, 2023

BUY
$2.1 - $6.37 $2.95 Million - $8.94 Million
1,404,108 Added 120009.23%
1,405,278 $4.95 Million
Q1 2023

May 11, 2023

SELL
$3.74 - $7.46 $7 - $14
-2 Reduced 0.17%
1,170 $4,000
Q4 2022

Feb 13, 2023

SELL
$4.56 - $6.61 $27 - $39
-6 Reduced 0.51%
1,172 $6,000
Q3 2022

Nov 10, 2022

SELL
$3.75 - $6.63 $296 - $523
-79 Reduced 6.28%
1,178 $7,000
Q2 2022

Aug 12, 2022

SELL
$2.11 - $4.06 $164,299 - $316,140
-77,867 Reduced 98.41%
1,257 $4,000
Q1 2022

May 13, 2022

SELL
$2.73 - $11.94 $3.44 Million - $15.1 Million
-1,260,903 Reduced 94.1%
79,124 $216,000
Q4 2021

Feb 14, 2022

SELL
$11.49 - $22.0 $8.79 Million - $16.8 Million
-765,395 Reduced 36.35%
1,340,027 $15.4 Million
Q3 2021

Nov 15, 2021

BUY
$16.35 - $23.4 $2.05 Million - $2.93 Million
125,175 Added 6.32%
2,105,422 $39.2 Million
Q2 2021

Aug 13, 2021

BUY
$17.81 - $27.48 $35.3 Million - $54.4 Million
1,980,247 New
1,980,247 $44.6 Million

Others Institutions Holding ANNX

About Annexon, Inc.


  • Ticker ANNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,617,700
  • Market Cap $347M
  • Description
  • Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...
More about ANNX
Track This Portfolio

Track Fmr LLC Portfolio

Follow Fmr LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.